| P2093 | author name string | Altaf Shah | |
| | Sumaiya Nabi | |
| | Nadeema Rafiq | |
| | Tauseef Nabi | |
| P2860 | cites work | N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study | Q51368693 |
| | Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure | Q51772704 |
| | Etiology and outcome for 295 patients with acute liver failure in the United States | Q52907526 |
| | High levels of serum interleukin-10 and tumor necrosis factor-alpha are associated with fatality in fulminant hepatitis | Q54586121 |
| | Aetiology and prognostic factors in acute liver failure in India | Q59829991 |
| | Detection of Acetaminophen Protein Adducts in Children With Acute Liver Failure of Indeterminate Cause | Q63170250 |
| | N-acetylcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism | Q68347307 |
| | Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients | Q68693274 |
| | Adverse reactions to N-acetylcysteine | Q70502062 |
| | Hypersensitivity-like reactions to N-acetylcysteine | Q70746951 |
| | Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure | Q71057903 |
| | Developing a World view toward acute liver failure | Q71257671 |
| | Paracetamol (acetaminophen) poisoning | Q72020055 |
| | In vivo evidence of enhanced guanylyl cyclase activation during the hyperdynamic circulation of acute liver failure | Q72662980 |
| | Oral N-acetylcysteine given intravenously for acetaminophen overdose: we shouldn't have to, but we must | Q74037579 |
| | Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure | Q74557771 |
| | Drug-induced liver injury at an Asian center: a prospective study | Q80085799 |
| | Controlled trial of exchange-transfusion therapy in fulminant hepatitis | Q93731472 |
| | Adverse reactions to acetylcysteine and effects of overdose | Q24543973 |
| | Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure | Q24635175 |
| | Acute liver failure of unknown pathogenesis: the hidden agenda | Q28252895 |
| | Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure | Q28333321 |
| | Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine | Q28334205 |
| | N-acetylcysteine in acute hepatic failure (non-paracetamol-induced). | Q31418472 |
| | Reactive oxygen and mechanisms of inflammatory liver injury | Q33999378 |
| | Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States | Q34165115 |
| | The management of fulminant hepatic failure. | Q34222402 |
| | Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. | Q34526044 |
| | Acute Liver Failure in the United States | Q34542334 |
| | Population-based surveillance for acute liver failure | Q34645492 |
| | Changing Patterns of Causation and the Use of Transplantation in the United Kingdom | Q35549228 |
| | Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report | Q35815187 |
| | Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. | Q36431416 |
| | Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure | Q37045805 |
| | The brain in acute liver failure. A tortuous path from hyperammonemia to cerebral edema | Q37339800 |
| | Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation | Q37466220 |
| | Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome | Q38859118 |
| | Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol | Q39251515 |
| | Acetaminophen Toxicity in an Urban County Hospital | Q39454333 |
| | Fulminant and subfulminant liver failure: definitions and causes | Q39742321 |
| | Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials | Q40167216 |
| | Fulminant hepatic failure: summary of a workshop | Q40560163 |
| | Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries | Q40622536 |
| | Fungal infection: a common, unrecognised complication of acute liver failure | Q40753267 |
| | N-acetylcysteine: pharmacological considerations and experimental and clinical applications. | Q40916404 |
| | Bacterial and fungal infection in acute liver failure | Q41347685 |
| | Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. | Q42165653 |
| | MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. | Q42168862 |
| | Fulminant or subfulminant non-A, non-B viral hepatitis: the role of hepatitis C and E viruses | Q43048465 |
| | Etiological role of hepatitis E virus in sporadic fulminant hepatitis | Q43049170 |
| | N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms. | Q43078904 |
| | Long-term follow-up of patients with acute liver failure of indeterminate aetiology | Q44624032 |
| | Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials | Q44719854 |
| | The systemic inflammatory response syndrome in acute liver failure | Q45243727 |
| | Etiology of fulminant hepatic failure: is another virus involved? | Q45774111 |
| | Treatment of fulminant hepatic failure with insulin and glucagon. A randomized, controlled trial. | Q45932651 |
| | Suspected drug-induced liver fatalities reported to the WHO database | Q46627287 |
| | Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure | Q46733753 |
| | Metabolic insights into the hepatoprotective role of N-acetylcysteine in mouse liver | Q46959059 |
| P433 | issue | 3 | |
| P921 | main subject | N-acetyl-L-cysteine | Q375613 |
| | liver failure | Q970208 |
| P304 | page(s) | 169-175 | |
| P577 | publication date | 2017-05-01 | |
| P1433 | published in | Saudi Journal of Gastroenterology | Q15817344 |
| P1476 | title | Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study | |
| P478 | volume | 23 | |